Arrowhead Pharmaceuticals, Inc. (ARWR) SEC Filings & Earnings Calls

Operating loss and cash burn

“Operating (loss) income $ (170,093) ... Net (loss) income attributable to Arrowhead $ (194,280)”

Dependence on partnership milestones

“Revenue is primarily driven by collaboration and license agreements; commercial revenue from REDEMPLO is partial.”

Commercial execution risk for REDEMPLO; prescription growth and payer coverage are key to revenue generation.

“REDEMPLO prescription volume roughly doubled; favorable policies in place for most significant U.S. payers”

Regulatory approval risk for plozasiran sNDA submission for sHTG; priority review voucher acquired to accelerate process.

“Acquired a U.S. FDA priority review voucher, which the company intends to use with its upcoming plozasiran sNDA submission”

Dependence on partnership with Madrigal for ARO-PNPLA3; milestone payments contingent on development success.

“Arrowhead is also eligible to receive development, regulatory, and sales milestone payments of up to $975 million” · word for word

No material risks identified; standard director appointment.

“Standard director appointment with no family relationships or arrangements.”

Operating loss and cash burn

“Operating (loss) income ( 141,260 ) ... Net (loss) income attributable to Arrowhead $ (132,732)”

Dependence on partnership milestones

“Revenue is primarily driven by collaboration and license agreements; commercial revenue from REDEMPLO is partial.”

Commercial execution risk for REDEMPLO; prescription growth and payer coverage are key to revenue generation.

“Total prescriptions received and in process to date exceeds 400; approximately 85% of prescriptions were for patients naive to the APOC3 class” · word for word

Pricing risk; WAC price set at $45,000 per patient per year, which may impact market access and payer negotiations.

“Updated the U.S. wholesale acquisition cost (WAC) of REDEMPLO to $45,000 per patient per year” · word for word

Regulatory approval risk for plozasiran sNDA submission for sHTG; priority review voucher acquired to accelerate process.

“Acquired a U.S. FDA priority review voucher, which the company intends to use with its upcoming plozasiran sNDA submission”

Revenue concentration on partnership milestones

“Revenue is heavily dependent on achieving milestones from partners like Sarepta and Novartis, which are not guaranteed.”

Significant operating losses and cash burn

“Research and development activities have required significant investment since the Company’s inception and are expected to continue to require significant cash expenditure in the future” · word for word

Commercial execution risk for first product launch; reliance on REDEMPLO for near-term revenue.

“First FDA-approved medicine; initial trends encouraging but early stage.”

Pipeline dependency on early-stage candidates; obesity data is interim and requires further validation.

“Interim clinical data on RNAi-based obesity candidates; Phase 1/2a trials ongoing.”

Revenue concentration on partnership milestones

“Revenue is heavily dependent on achieving milestones from partners like Sarepta and Novartis, which are not guaranteed.”

Potential dilution from conversion of notes if stock price exceeds conversion price.

“Conversion price $87.07; stock may trade above that level.”

Debt service obligations; though zero-coupon, special interest may accrue up to 0.50% upon certain events.

“Special interest may accrue on the Notes at a rate per annum not exceeding 0.50% upon the occurrence of certain events.” · word for word

Significant dilution from equity offering; pre-funded warrants add further potential dilution.

“3.1M shares + 1.55M pre-funded warrants + 0.456M over-allotment shares.”

Increased leverage from convertible notes; though zero-coupon, potential conversion dilutes equity.

“$700M convertible notes due 2032.”

Dependence on partnership milestones and regulatory approvals for future revenue.

“Milestone payments from Novartis and Sarepta are contingent on development and regulatory achievements.”

Commercial execution risk for REDEMPLO launch.

“First FDA-approved medicine; transitioning to commercial stage.”

FDA Regulatory Disruption

“FDA may lack adequate staff and resources to meet current review, approval, and inspection schedules, which could delay our anticipated timelines.” · word for word

Drug Pricing Pressure

“In May 2025, the Trump administration issued an executive order entitled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.'” · word for word

Tariff Input Cost Pressure

“In September 2025, the current Presidential Administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceutical products.” · word for word